Research Letter: PDF OnlySafety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIVRuddy, Jake A.a; Boyarsky, Brian J.a; Bailey, Justin R.b; Karaba, Andrew H.b; Garonzik-Wang, Jacqueline M.a; Segev, Dorry L.a,c; Durand, Christine M.b; Werbel, William A.bAuthor Information aDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD bDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD cDepartment of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD. Correspondence to William A. Werbel, MD, Research Fellow, Infectious Diseases, Department of Medicine, Johns Hopkins University, 725 N. Wolfe Street, 2nd Floor, Baltimore, MD 21205. Tel: +443 287 4840; fax: +410 502 7029; e-mail: [email protected] Received 13 May, 2021 Revised 28 June, 2021 Accepted 1 July, 2021 Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com). AIDS: July 08, 2021 - Volume - Issue - doi: 10.1097/QAD.0000000000003017 Free SDC PAP Metrics Abstract This study of SARS-CoV-2 mRNA vaccination in 14 persons with HIV demonstrated uniformly high anti-SARS-CoV-2 receptor binding domain antibody titers after two doses, despite varied titers after a single dose. The majority of vaccine reactions were mild and no adverse events occurred. Copyright © 2021 Wolters Kluwer Health, Inc.